MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: The preferred management for women with stage II or locally advanced breast cancer (LABC) is neoadjuvant chemotherapy. Pathologic response to chemotherapy has been shown to be an excellent predictor of outcome. Surrogates that can predict pathologic response and outcome will fuel future changes in management. Magnetic resonance imaging (MRI) demonstrates that patients with LABC have distinct tumor patterns. We investigated whether or not these patterns predict response to therapy.
Methods: Thirty-three women who received neoadjuvant doxorubicin and cyclophosphamide chemotherapy for 4 cycles and serial breast MRI scans before and after therapy were evaluated for this study. Response to therapy was measured by change in the longest diameter on the MRI.
Results: Five distinct imaging patterns were identified: circumscribed mass, nodular tissue infiltration diffuse tissue infiltration, patchy enhancement, and septal spread. The likelihood of a partial or complete response as measured by change in longest diameter was 77%, 37.5%, 20%, and 25%, respectively.
Conclusions: MRI affords three-dimensional characterization of tumors and has revealed distinct patterns of tumor presentation that predict response. A multisite trial is being planned to combine imaging and genetic information in an effort to better understand and predict response and, ultimately, to tailor therapy and direct the use of novel agents.
- Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 1991; 324: 160–8. CrossRef
- Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group [see comments]. Lancet 1998; 352: 930–42.
- Heywang SH, Hahn D, Schmidt H, et al. MR imaging of the breast using gadolinium-DTPA. J Comput Assist Tomogr 1986; 10: 199–204.
- Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 1989; 170: 681–6.
- Heywang SH, Wolf A, Pruss E, Hilbertz T, Eiermann W, Permanetter W. MR imaging of the breast with Gd-DTPA: use and limitations. Radiology 1989; 171: 95–103.
- Revel D, Brasch RC, Paajanen H, et al. Gd-DTPA contrast enhancement and tissue differentiation in MR imaging of experimental breast carcinoma. Radiology 1986; 158: 319–23.
- Pierce WB, Harms SE, Flamig DP, Griffey RH, Evans WP, Hagans JE. Three-dimensional gadolinium-enhanced MR imaging of the breast: pulse sequence with fat suppression and magnetization transfer contrast. Work in progress. Radiology 1991; 181: 757–63.
- Stack JP, Redmond OM, Codd MB, Dervan PA, Ennis JT. Breast disease: tissue characterization with Gd-DTPA enhancement profiles. Radiology 1990; 174: 491–4.
- Harms SE, Flamig DP, Hesley KL, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993; 187: 493–501.
- Orel SG, Schnall MD, LiVolsi VA, Troupin RH. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. Radiology 1994; 190: 485–93.
- Gribbestad IS, Nilsen G, Fjosne H, et al. Contrast-enhanced magnetic resonance imaging of the breast. Acta Oncol 1992; 31: 833–42.
- Flickinger FW, Allison JD, Sherry RM, Wright JC. Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. Magn Reson Imaging 1993; 11: 617–20. CrossRef
- Dao TH, Rahmouni A, Campana F, Laurent M, Asselain B, Fourquet A. Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 187: 751–5.
- Gilles R, Guinebretiere JM, Shapeero LG, et al. Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. Radiology 1993; 188: 473–8.
- Heywang SH, Hilbertz T, Pruss E, et al. [Dynamic contrast medium studies with flash sequences in nuclear magnetic resonance tomography of the breast]. Digitale Bilddiagn 1988; 8: 7–13.
- Rubens D, Totterman S, Chacko AK, et al. Gadopentetate dimeglumine-enhanced chemical-shift MR imaging of the breast. AJR Am J Roentgenol 1991; 157: 267–70.
- Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 1994; 193: 777–81.
- Hulka CA, Smith BL, Sgroi DC, et al. Benign and malignant breast lesions: differentiation with echo-planar MR imaging. Radiology 1995; 197: 33–8.
- Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 1999; 17: 110–9.
- Abraham DC, Jones RC, Jones SE, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996; 78: 91–100. CrossRef
- Davis PL, Staiger MJ, Harris KB, et al. Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography. Breast Cancer Res Treat 1996; 37: 1–9.
- Rieber A, Zeitler H, Rosenthal H, et al. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 1997; 70: 452–8.
- Gilles R, Guinebretiere JM, Toussaint C, et al. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 1994; 191: 633–8.
- Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy [see comments]. J Clin Oncol 1999; 17: 460–9.
- Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999; 230: 72–8.
- Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998; 176: 502–9.
- Kuerer HM, Newman LA, Fornage BD, et al. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer [see comments]. Ann Surg Oncol 1998; 5: 673–80.
- Kuerer HM, Newman LA, Buzdar AU, et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status [see comments]. Cancer J Sci Am 1998; 4: 230–6.
- Pierga JY. Prognostic value of node involvement after preoperative chemotherapy in 507 patients with operable breast cancer, Proceedings of ASCO, 1998. Vol. 17.
- Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994; 73: 362–9.
- James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement [see comments]. J Natl Cancer Inst 1999; 91: 523–8.
- Venables WN, Ripley BD. Modern Applied Statistics with S-Plus. Vol. 2. New York: Springer-Verlag, 1997: 247–266.
- Esserman L, Kaplan E, Sudilovsky D, Miller J, Hylton N. MRI can predict breast conservation in patients undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat 2000; 64: 116.
- Weiss RB, Rifkin RM, Stewart FM, et al. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet 2000; 355: 999–1003.
- Stadtmauer EA, O’Neill A, Goldstein LJ. Phase III randomized trial of high-dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared with maintenance chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the “Ph iladelphia Intergroup Study (PBT-1). Proc ASCO 1999; 18: 1A(abstr 1).
- Peters WP, Rosner G, Vredenburgh J. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG9114/NCIC MA-13. Proc ASCO 1999; 18: 1(abstr 2).
- Esserman L, Hylton N, George T, Weidner N. Contrast-enhanced magnetic resonance imaging to assess tumor histopathology and angiogenesis in breast carcinoma. Breast J 1999; 5: 13–21.
- MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer
Annals of Surgical Oncology
Volume 8, Issue 6 , pp 549-559
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Magnetic resonance imaging
- Neoadjuvant chemotherapy
- Locally advanced breast cancer
- Industry Sectors
- Author Affiliations
- 1. Department of Surgery, University of California, San Francisco, California
- 4. Department of Radiology, University of California, San Francisco, California
- 6. 2356 Sutter Street, 6th Floor, San Francisco, CA, 94115
- 2. Department of Bioengineering, University of California, San Francisco, California
- 5. Department of Medicine, University of California, San Francisco, California
- 3. Department of Pathology, University of California, San Francisco, California